GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Neogen Corp (NAS:NEOG) » Definitions » Net Current Asset Value

Neogen (Neogen) Net Current Asset Value

: $-3.85 (As of Feb. 2024)
View and export this data going back to 1989. Start your Free Trial

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Neogen's net current asset value per share for the quarter that ended in Feb. 2024 was $-3.85.

The historical rank and industry rank for Neogen's Net Current Asset Value or its related term are showing as below:

During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Neogen was 14.42. The lowest was 4.38. And the median was 9.22.

NEOG's Price-to-Net-Current-Asset-Value is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 4.35
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Neogen Net Current Asset Value Historical Data

The historical data trend for Neogen's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neogen Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Net Current Asset Value
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.75 4.40 4.76 4.84 -3.86

Neogen Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Net Current Asset Value Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.83 -3.86 -3.84 -3.84 -3.85

Competitive Comparison

For the Diagnostics & Research subindustry, Neogen's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neogen Price-to-Net-Current-Asset-Value Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Neogen's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Neogen's Price-to-Net-Current-Asset-Value falls into.



Neogen Net Current Asset Value Calculation

Neogen's Net Current Asset Value (NCAV) per share for the fiscal year that ended in May. 2023 is calculated as

Net Current Asset Value Per Share(A: May. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(585.931-1420.215-0-0)/216.245
=-3.86

Neogen's Net Current Asset Value (NCAV) per share for the quarter that ended in Feb. 2024 is calculated as

Net Current Asset Value Per Share(Q: Feb. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(602.471-1436.318-0-0)/216.608
=-3.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neogen  (NAS:NEOG) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Neogen Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Neogen's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Neogen (Neogen) Business Description

Traded in Other Exchanges
Address
620 Lesher Place, Lansing, MI, USA, 48912
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety (70% of post-merger sales), Neogen performs diagnostics to detect unintended substances in food and animal feed, such as pathogens, allergens, and drug residues, for food and feed processing companies. In animal safety (20% of post-merger sales), Neogen sells veterinary instruments, pharmaceuticals, disinfectants, and genomics tests for animals, including cattle, horses, and canines. Sales in the United States account for 60% of total revenue, while international markets, including Canada, Europe, Asia, and Latin America, account for the remaining 40%.
Executives
William T Boehm director
Douglas Edward Jones officer: Vice President, CCO 620 LESHER PLACE, LANSING MI 48912
Jason Warren Lilly officer: Vice President 620 LESHER PLACE, LANSING MI 48912
James P Tobin director 620 LESHER PLACE, LANSING MI 48895
David H. Naemura officer: VP & CFO C/O GATES INDUSTRIAL CORPORATION PLC, 1144 FIFTEENTH STREET, SUITE 1400, DENVER CO 80202
Amy M Rocklin officer: Chief Legal & Reg. Officer 620 LESHER PLACE, LANSING MI 48912
Steven J. Quinlan officer: VP & CFO 620 LESHER PLACE, LANSING MI 48912
Jeffrey D Capello director C/O NEOGEN CORP., 620 LESHER PLACE, LANSING MI 48912
Aashima Gupta director C/O NEOGEN CORPORATION, 620 LESHER PLACE, LANSING MI 48912
John Edward Adent officer: Chief Executive Officer 822 7TH STREET, SUITE 740, GREELEY CO 80631
Darci L Vetter director 620 LESHER PLACE, LANSING MI 48912
Ronald D Green director 620 LESHER PLACE, LANSING MI 48912
James C Borel director 1007 MARKET STREET, WILMINGTON DE 19898
Terri A Morrical officer: General Manager
G Bruce Papesh director 726 APPLEGATE LANE, EAST LANSING MI 48823